Key Highlights
- BioAge Labs appoints Jean-Pierre Garnier, PhD, as Chair of the Board of Directors.
- Garnier brings extensive leadership experience from GlaxoSmithKline and multiple board positions.
- James Healy, MD, PhD, former Chair, remains on the Board, contributing to clinical development strategy.
Source: Business Wire
Notable Quotes
- “JP’s extensive experience in leading biotech and pharmaceutical companies through critical growth phases will be invaluable as we progress our lead compound, azelaprag.” — Kristen Fortney, PhD, CEO and Co-founder at BioAge Labs
- “I look forward to working alongside Kristen and BioAge’s talented leadership team to fully realize the potential of azelaprag.” — Jean-Pierre Garnier, PhD, Chair of the Board at BioAge Labs
SoHC's Take
The appointment of Jean-Pierre Garnier as Chair of BioAge Labs’ Board of Directors signifies a strategic move to leverage his vast experience in guiding biotech and pharmaceutical companies through pivotal growth stages. Garnier’s background, particularly his tenure at GlaxoSmithKline and his involvement in significant mergers and acquisitions, aligns well with BioAge’s current trajectory in advancing treatments for metabolic diseases. This leadership transition is likely to provide BioAge with the operational acumen and strategic insight needed to propel its innovative therapies, particularly azelaprag, through critical phases of clinical development and into the market.
